Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls

T. J. Montine, Jeffrey Kaye, K. S. Montine, L. McFarland, J. D. Morrow, Joseph Quinn

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95% sensitivity, 50% specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84% sensitivity, 89% specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.

Original languageEnglish (US)
Pages (from-to)510-512
Number of pages3
JournalArchives of Pathology and Laboratory Medicine
Volume125
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

F2-Isoprostanes
Cerebrospinal Fluid
Dementia
Alzheimer Disease
Sensitivity and Specificity
Clinical Laboratory Techniques
Routine Diagnostic Tests
Gas Chromatography-Mass Spectrometry
Free Radicals
Biomarkers
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. / Montine, T. J.; Kaye, Jeffrey; Montine, K. S.; McFarland, L.; Morrow, J. D.; Quinn, Joseph.

In: Archives of Pathology and Laboratory Medicine, Vol. 125, No. 4, 2001, p. 510-512.

Research output: Contribution to journalArticle

@article{eabf5982dd814f43b7fc8aca88cd7432,
title = "Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls",
abstract = "Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95{\%} sensitivity, 50{\%} specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90{\%} sensitivity, 83{\%} specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84{\%} sensitivity, 89{\%} specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.",
author = "Montine, {T. J.} and Jeffrey Kaye and Montine, {K. S.} and L. McFarland and Morrow, {J. D.} and Joseph Quinn",
year = "2001",
language = "English (US)",
volume = "125",
pages = "510--512",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "4",

}

TY - JOUR

T1 - Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls

AU - Montine, T. J.

AU - Kaye, Jeffrey

AU - Montine, K. S.

AU - McFarland, L.

AU - Morrow, J. D.

AU - Quinn, Joseph

PY - 2001

Y1 - 2001

N2 - Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95% sensitivity, 50% specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84% sensitivity, 89% specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.

AB - Objective. - To test the hypothesis that quantification of cerebrospinal fluid (CSF) F2-isoprostanes (F2-IsoPs), in vivo biomarkers of free radical damage, along with CSF Aβ42 and tau levels improves laboratory diagnostic accuracy for Alzheimer disease (AD). Participants. - Patients with probable AD (n = 19), dementias other than AD (n = 8), and age-matched controls (n = 10). Main Outcome Measures. - Cerebrospinal fluid concentrations of Aβ42 and tau were determined by a commercially available test (Athena Diagnostics, Worcester, Mass). Cerebrospinal fluid F2-IsoP levels were quantified by gas chromatography/mass spectrometry. Results. - Individuals were classified as AD or non-AD by a published method using CSF Aβ42 and tau levels (95% sensitivity, 50% specificity), by CSF F2-IsoP levels greater than 25 pg/mL and Aβ42 concentrations less than 1125 pg/mL (90% sensitivity, 83% specificity), and by combined analysis using CSF F2-IsoP, Aβ42, and tau levels (84% sensitivity, 89% specificity). Conclusion. - Cerebrospinal fluid F2-IsoP quantification may enhance the accuracy of the laboratory diagnosis of AD.

UR - http://www.scopus.com/inward/record.url?scp=0034745018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034745018&partnerID=8YFLogxK

M3 - Article

VL - 125

SP - 510

EP - 512

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 4

ER -